Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 267

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 267
---
3, 2024, the Company
extended the due date of the 2020 Notes until April 30, 2024 and, subsequently, on April 26, 2024, further extended the due date until
May 27, 2024.

| b. | In October 2024,                                                                                 
 the Company entered into an addendum to the 2020 CLAs (the “October 2024 CLA Addendum”)          
 pursuant to which the Company will issue additional notes up to an additional aggregate amount   
 of $450 to certain lenders (the “Participating Lenders”). Pursuant to the October                
 2024 CLA Addendum, the 2020 Notes held by the non-participating lenders will bear interest       
 at 8% per annum until maturity commencing as of July 1, 2024, and the 2020 Notes held by         
 the Participating Lenders commencing on March 31, 2025. In addition, pursuant to the October     
 2024 CLA Addendum, upon the earlier of March 31, 2025 or occurrence of an IPO, the 2020 Notes    
 principal and accrued interest will be automatically converted into 609,887 Ordinary Shares      
 based on a pre money valuation of $5,150. In addition, upon conversion of the CLAs to Ordinary   
 Shares the Company will issue additional 553,640 Ordinary Shares to the Participating Lenders    
 which presents the additional amount provided by Participating Lenders, the applicable accrued   
 interest and the amount of $340 as a risk premium. As of December 31, 2024, the Company received 
 proceeds of $450 proceeds from the issuance of the additional 2020 Notes. On March 31, 2025,     
 the Company and the lenders signed an amendment to the loan agreement to extend the maturity     
 date until the earlier of August 31, 2025 or consummation of an IPO.                             |

The Company estimates the fair
value of the 2020 Notes using the Probability-Weighted Expected Return Method (PWERM). For years ended December 31, 2024 and 2023, the
Company recorded an income/ (expense) of $3,483 and $(2,019) for the revaluation of such 2020 Notes, within financial expense, net in
the statements of comprehensive loss.

A summary of significant unobservable
inputs (Level 3 inputs) used in measuring the fair value